In 2017, the Japanese company Takeda Pharmaceutical Company acquired the U.S. company ARIAD Pharmaceuticals at leader in oncology therapies for $5.2 billion. What economic advantages might the two drug companies be expecting from their marriage? More generally, what economic forces underlie the ongoing process of consolidation and globalization in the world pharmaceutical industry? Consider the merger’s impact in the areas of R&D, marketing, and production.